
Marcus D Säemann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8289999/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Response to: Correspondence on â€ [~] Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors' by Patoulias. Annals of the Rheumatic Diseases, 2023, 82, e196-e196.	0.9	2
2	Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors. Annals of the Rheumatic Diseases, 2022, 81, 614-617.	0.9	24
3	Critical Role of Neprilysin in Kidney Angiotensin Metabolism. Circulation Research, 2020, 127, 593-606.	4.5	23
4	Intrarenal Renin-Angiotensin-System Dysregulation after Kidney Transplantation. Scientific Reports, 2019, 9, 9762.	3.3	8
5	Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. American Journal of Transplantation, 2019, 19, 907-919.	4.7	82
6	Low- and High-renin Heart Failure Phenotypes with Clinical Implications. Clinical Chemistry, 2018, 64, 597-608.	3.2	52
7	Fluid status and outcome in patients with heart failure and preserved ejection fraction. International Journal of Cardiology, 2017, 230, 476-481.	1.7	26
8	Molecular remodeling of the renin-angiotensin system after kidney transplantation. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2017, 18, 147032031770523.	1.7	8
9	Effects of direct renin inhibition versus angiotensin II receptor blockade on angiotensin profiles in non-diabetic chronic kidney disease. Annals of Medicine, 2017, 49, 525-533.	3.8	16
10	04.05â€The metabolic checkpoint kinase mtor regulates the rheumatoid mesenchymal tissue response to inflammation. , 2017, , .		0
11	Intravenous Fluid Challenge Decreases Intracellular Volume: A Bioimpedance Spectroscopy-Based Crossover Study in Healthy Volunteers. Scientific Reports, 2017, 7, 9644.	3.3	8
12	Effects of angiotensin-converting-enzyme inhibitor therapy on the regulation of the plasma and cardiac tissue renin-angiotensin system in heart transplant patients. Journal of Heart and Lung Transplantation, 2017, 36, 355-365.	0.6	14
13	Blood volume-monitored regulation of ultrafiltration to decrease the dry weight in fluid-overloaded hemodialysis patients: a randomized controlled trial. BMC Nephrology, 2017, 18, 238.	1.8	33
14	Sports and HDL-Quality Reflected By Serum Amyloid A and Surfactant Protein B. International Journal of Medical Sciences, 2017, 14, 1040-1048.	2.5	4
15	Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDlalysis (VIVALDI). PLoS ONE, 2017, 12, e0169400.	2.5	51
16	Fasting metabolism modulates the interleukin-12/interleukin-10 cytokine axis. PLoS ONE, 2017, 12, e0180900.	2.5	12
17	MO020CHYMASE AND NEPRILYSIN ARE KEY REGULATORS OF THE CLASSICAL AND ALTERNATIVE RENIN ANGIOTENSIN SYSTEM (RAS) AFTER KIDNEY TRANSPLANTATION: IMPLICATIONS FOR RAS BLOCKINGTHERAPY. Nephrology Dialysis Transplantation, 2016, 31, i36-i36.	0.7	0
18	SP479HDL CHOLESTEROL EFFLUX IS NOT PREDICTIVE OF CARDIOVASCULAR RISK IN DIABETIC PATIENTS ON HEMODIALYSIS. Nephrology Dialysis Transplantation, 2016, 31, i253-i253.	0.7	0

Marcus D Sämann

#	Article	IF	CITATIONS
19	Applied immuno-epidemiological research: an approach for integrating existing knowledge into the statistical analysis of multiple immune markers. BMC Immunology, 2016, 17, 11.	2.2	7
20	Neprilysin is a Mediator of Alternative Renin-Angiotensin-System Activation in the Murine and Human Kidney. Scientific Reports, 2016, 6, 33678.	3.3	70
21	Conversion from Tacrolimus to Cyclosporine A Improves Glucose Tolerance in HCV-Positive Renal Transplant Recipients. PLoS ONE, 2016, 11, e0145319.	2.5	5
22	Prophylactic <scp>CMV</scp> therapy does not improve threeâ€yr patient and graft survival compared to preemptive therapy. Clinical Transplantation, 2015, 29, 1230-1238.	1.6	8
23	FP274ACE-INDEPENDENT RAS ENZYME ACTIVITIES IN HEART TRANSPLANT PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD). Nephrology Dialysis Transplantation, 2015, 30, iii158-iii159.	0.7	Ο
24	Diabetes-related end-stage renal disease in Austria 1965–2013. Nephrology Dialysis Transplantation, 2015, 30, 1920-1927.	0.7	25
25	Antidiabetic therapy in post kidney transplantation diabetes mellitus. Transplantation Reviews, 2015, 29, 145-153.	2.9	11
26	Molecular regulation of the renin–angiotensin system in haemodialysis patients. Nephrology Dialysis Transplantation, 2015, 30, 115-123.	0.7	34
27	Comparison of glycemic control and variability in patients with type 2 and posttransplantation diabetes mellitus. Journal of Diabetes and Its Complications, 2015, 29, 1211-1216.	2.3	13
28	Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk. European Heart Journal, 2015, 36, ehv352.	2.2	116
29	Bioimpedance Spectroscopy for Assessment of Volume Status in Patients before and after General Anaesthesia. PLoS ONE, 2014, 9, e111139.	2.5	25
30	Sex-Specific Differences in Hemodialysis Prevalence and Practices and the Male-to-Female Mortality Rate: The Dialysis Outcomes and Practice Patterns Study (DOPPS). PLoS Medicine, 2014, 11, e1001750.	8.4	184
31	Long-Term Outcome of Anti-Glomerular Basement Membrane Antibody Disease Treated with Immunoadsorption. PLoS ONE, 2014, 9, e103568.	2.5	43
32	Fluid overload in hemodialysis patients: a cross-sectional study to determine its association with cardiac biomarkers and nutritional status. BMC Nephrology, 2013, 14, 266.	1.8	77
33	The versatility of HDL: a crucial antiâ€inflammatory regulator. European Journal of Clinical Investigation, 2010, 40, 1131-1143.	3.4	77
34	Maintenance immunosuppressive therapy in adult renal transplantation: A single center analysis. Transplant Immunology, 2008, 20, 14-20.	1.2	6
35	Uncovering host defences in the urinary tract: cathelicidin and beyond. Nephrology Dialysis Transplantation, 2006, 22, 347-349.	0.7	7
36	Tamm-Horsfall glycoprotein links innate immune cell activation with adaptive immunity via a Toll-like receptor-4–dependent mechanism. Journal of Clinical Investigation, 2005, 115, 468-475.	8.2	131

#	Article	IF	CITATIONS
37	Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic transplantation. Transplant International, 2004, 17, 481-489.	1.6	6
38	Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic transplantation. Transplant International, 2004, 17, 481-489.	1.6	10